Evidence map›Paper›PMID 35142364›Full record

ArticleJournal of cell science2022

Hedgehog pathway modulation by glypican 3-conjugated heparan sulfate.

Yulu Cherry Liu, Bradley M Wierbowski, Adrian Salic

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yulu Cherry LiuDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0003-4861-6915
Bradley M WierbowskiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-1967-5919
Adrian SalicDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0748-9545
Harvard University · US

Funding

Molecular, Cellular, & Developmental Dynamics PhD ProgramT32GM007226 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI VAN VACTOR, DAVID L. · 1985 to 2021
$14.4M
Sending and receiving Hedgehog signalsR01GM122920 · NIGMS · HARVARD MEDICAL SCHOOL · PI SALIC, ADRIAN · 2018 to 2023
$2.7M
Transducing Hedgehog signals across the plasma membraneR01GM135262 · NIGMS · HARVARD MEDICAL SCHOOL · PI SALIC, ADRIAN · 2020 to 2023
$1.7M
Molecular Mechanisms of SCUBE2-Mediated Sonic Hedgehog Release and DeliveryF31GM120833 · NIGMS · HARVARD MEDICAL SCHOOL · PI WIERBOWSKI, BRADLEY MICHAEL · 2016 to 2017
$68k
Kidney Foundation of CanadaNIGMS NIH HHS F31 GM120833NIGMS NIH HHS R01 GM122920NIGMS NIH HHS R01 GM135262NIGMS NIH HHS T32 GM007226
6 · The paper itself

Abstract

Glypicans are a family of cell surface heparan sulfate proteoglycans that play critical roles in multiple cell signaling pathways. Glypicans consist of a globular core, an unstructured stalk modified with sulfated glycosaminoglycan chains, and a glycosylphosphatidylinositol anchor. Though these structural features are conserved, their individual contribution to glypican function remains obscure. Here, we investigate how glypican 3 (GPC3), which is mutated in Simpson-Golabi-Behmel tissue overgrowth syndrome, regulates Hedgehog signaling. We find that GPC3 is necessary for the Hedgehog response, surprisingly controlling a downstream signal transduction step. Purified GPC3 ectodomain rescues signaling when artificially recruited to the surface of GPC3-deficient cells but has dominant-negative activity when unattached. Strikingly, the purified stalk, modified with heparan sulfate but not chondroitin sulfate, is necessary and sufficient for activity. Our results demonstrate a novel function for GPC3-associated heparan sulfate and provide a framework for the functional dissection of glycosaminoglycans by in vivo biochemical complementation. This article has an associated First Person interview with the first author of the paper.

Indexed as

Abnormalities, MultipleGlypicansHedgehog ProteinsHeparan SulfateArrhythmias, CardiacGenetic Diseases, X-LinkedGigantismHeart Defects, CongenitalHeparan Sulfate ProteoglycansHumansIntellectual DisabilitySignal TransductionGlypicansGPC3 protein, humanHedgehog ProteinsHeparan SulfateHeparan Sulfate ProteoglycansGlycosaminoglycansGlypicanHedgehogHeparan sulfateSignaling

Identifiers

PMID35142364
PMCPMC8977055
OpenAlexW4211148931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.